ArticleJournal of thoracic disease2025
Prevalence of
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04742192 (A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients With Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients With Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although targeted and immune-based therapies are now recommended for early-stage non-small cell lung cancer (NSCLC), data on biomarker prevalence in Latin America (LATAM) remain limited. The aim of the descriptive, observational, real-world, EARLY-EGFR (NCT04742192) study was to determine the frequency of Methods: The LATAM subset prospectively enrolled patients with surgically resected stage IA-IIIB [American Joint Committee on Cancer (AJCC) 8th edition] non-squamous NSCLC from March 2021 to October 2022. Primary endpoint was Results: Of 80 patients (mean ± standard deviation age of 66.5±9.7 years) enrolled, 67.5% were females and 57.5% were never smokers. Most patients had pathological stage (PS) stage I (66.3%) NSCLC, with 85.0% patients having pN0; all patients had adenocarcinoma. Most patients (61.3%) had right lung involvement. More than one-third of patients (39.5%; 30/76) had Conclusions: The LATAM subset shows an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.